- Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
-
Mooij CF, Tacke CE, van Albada ME, Barthlen W, Bikker H, Mohnike K, Oomen MW, van Trotsenburg AP, Zwaveling-Soonawala N
- KMID: 2523835
- Ann Pediatr Endocrinol Metab.
- 2021 Dec;26(4):278-283.
- doi: 10.6065/apem.2142010.005
ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases. Current treatment protocols include the first-generation... -
- CITED
-
- Close
- SHARE
-
- Close
